Alexandra Gangi, MD (@agangimd) 's Twitter Profile
Alexandra Gangi, MD

@agangimd

Surgical Oncologist @CedarsSinai | Lover of all things HPB/GI Surgical Onc I Views are my own

ID: 977731116672143360

calendar_today25-03-2018 02:17:18

1,1K Tweet

2,2K Followers

1,1K Following

Julie Hallet (@halletjulie) 's Twitter Profile Photo

When NANETS goes to Mexico City 🦓 Surgical management of SB-NETs: tailor resection to disease! ✅Spare bowel ✅Spare liver More about control than cure 💭 Some great discussions with attendees! Many questions to be answered 👉🏻CUTNETs Group has work to do!

When <a href="/NANETS1/">NANETS</a> goes to Mexico City 🦓

Surgical management of SB-NETs: tailor resection to disease! 
✅Spare bowel
✅Spare liver
More about control than cure 💭

Some great discussions with attendees!
Many questions to be answered 👉🏻<a href="/CUTNETs_/">CUTNETs Group</a> has work to do!
Thor Halfdanarson (@oncothor) 's Twitter Profile Photo

Much awaited results of COMPETE presented by Jaume Capdevila at ENETS #ENETS2024. The primary endpoint, PFS, was better than the comparison, everolimus. Mostly G2 and second-line therapy. Highly clinically relevant and significant.

Much awaited results of COMPETE presented by <a href="/Ja_Capdevila/">Jaume Capdevila</a> at <a href="/ENETS_ORG/">ENETS</a> #ENETS2024. The primary endpoint, PFS, was better than the comparison, everolimus. Mostly G2 and second-line therapy. Highly clinically relevant and significant.
Neuroendocrine Cancer Foundation (@ncfcancer) 's Twitter Profile Photo

#enets2025 - Jaume Capdevila presents the much anticipated results of ITM’s COMPETE study, the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus). Positive results & good tolerability suggest potential for 1L or 2L treatment GEPNETS

#enets2025 - <a href="/Ja_Capdevila/">Jaume Capdevila</a> presents the much anticipated results of ITM’s COMPETE study, the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus). Positive results &amp; good tolerability suggest potential for 1L or 2L treatment GEPNETS
ASCI (@the_asci) 's Twitter Profile Photo

In colorectal cancer, liver metastasis is enhanced by fat build-up in the liver, but the mechanism was unclear. ASCI member Ekihiro Seki & team Cedars-Sinai now show steatotic liver alters the fibrotic tumor environment, and inhibition of HA synthesis by 4-MU attenuates the

In colorectal cancer, liver metastasis is enhanced by fat build-up in the liver, but the mechanism was unclear.

ASCI member Ekihiro Seki &amp; team <a href="/CedarsSinai/">Cedars-Sinai</a> now show steatotic liver alters the fibrotic tumor environment, and inhibition of HA synthesis by 4-MU attenuates the
Julie Hallet (@halletjulie) 's Twitter Profile Photo

🦓 NANETS is going to LA ⭐️🍿🎥 If you’re around and want to learn more about #NETs, join us! I’ll be there along with Thor Halfdanarson Callisia Clarke MD Jess Maxwell MD MBA Laleh Melstrom & many more 📆 May 17 🔗 nanets.net/component/civi… Thanks Alexandra Gangi, MD for organizing!

🦓 <a href="/NANETS1/">NANETS</a> is going to LA ⭐️🍿🎥

If you’re around and want to learn more about #NETs, join us! I’ll be there along with <a href="/OncoThor/">Thor Halfdanarson</a> <a href="/DrCNClarke/">Callisia Clarke MD</a> <a href="/JMaxCutsNETs/">Jess Maxwell MD MBA</a> <a href="/laleh_melstrom/">Laleh Melstrom</a> &amp; many more 

📆 May 17
🔗 nanets.net/component/civi…

Thanks <a href="/AGangiMD/">Alexandra Gangi, MD</a> for organizing!
Julie Hallet (@halletjulie) 's Twitter Profile Photo

Symptoms & quality of life are key in #NETs care New tools🧰 from @asco for symtpom management in well-diff GEP-NETs ☑️carcinoid syndrome, carcinoid heart disease, carcinoid crisis & functional PNETs ☑️surgrery, liver-directed therapy & systemic 🔗📝ascopubs.org/doi/10.1200/OP…

Symptoms &amp; quality of life are key in #NETs care 

New tools🧰 from @asco for symtpom management in well-diff GEP-NETs
☑️carcinoid syndrome, carcinoid heart disease, carcinoid crisis &amp; functional PNETs
☑️surgrery, liver-directed therapy &amp; systemic 

🔗📝ascopubs.org/doi/10.1200/OP…
Jun Gong (@jgong15) 's Twitter Profile Photo

Huge congrats to Cancer at Cedars-Sinai 2nd yr heme/onc fellow Dr. Louisa Liu for her 2025 Conquer Cancer, the ASCO Foundation #YIA 🙌❗️❗️Way to represent Cedars-Sinai. Proud to serve as her mentor for this award. As a former class of 2022 ASCO #CCF #CDA recipient, I know how impactful this award will be

Huge congrats to <a href="/CSCancerCenter/">Cancer at Cedars-Sinai</a> 2nd yr heme/onc fellow Dr. Louisa Liu for her 2025 <a href="/ConquerCancerFd/">Conquer Cancer, the ASCO Foundation</a> #YIA 🙌❗️❗️Way to represent <a href="/CedarsSinai/">Cedars-Sinai</a>. Proud to serve as her mentor for this award. As a former class of 2022 <a href="/ASCO/">ASCO</a> #CCF #CDA recipient, I know how impactful this award will be
NEJM (@nejm) 's Twitter Profile Photo

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Presented at #ASCO25: 

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:
Sharlene Gill, MD, MPH, MBA, FASCO (@gillsharlene) 's Twitter Profile Photo

#ASCO25 ASCO NEJM ✅ Exercise Saves Lives After Colon Cancer ➡️ come watch Dr Chris Booth present the results of the ph3 CO.21 CHALLENGE study - don’t walk, run! 🏃🏃🏻‍♂️🏃 Hall B1 430-6pm 🙏 to our patients, my GI group CCTG 🇨🇦 and our partner GI Cancer Institute and AGITG 🇦🇺🇳🇿for

#ASCO25 <a href="/ASCO/">ASCO</a> <a href="/NEJM/">NEJM</a> 
✅ Exercise Saves Lives After Colon Cancer

➡️ come watch Dr Chris Booth present the results of the ph3 CO.21 CHALLENGE study - don’t walk, run! 🏃🏃🏻‍♂️🏃
Hall B1 430-6pm

🙏 to our patients, my GI group <a href="/CDNCancerTrials/">CCTG</a> 🇨🇦 and our partner <a href="/GICancer/">GI Cancer Institute and AGITG</a> 🇦🇺🇳🇿for
Jun Gong (@jgong15) 's Twitter Profile Photo

Yelena Y. Janjigian MD plenary session PhIII MATTERHORN periop FLOT +/- durva (up to 1 yr) in stage II-IVa G/GEJ adenoCA (90% PD-L1>1) ➡️ 29% reduction in PD or death, superior EFS (HR 0.71) w/durva arm. pCR 19% vs 7% (52% finished adj durva, 61% finished adj FLOT). #ASCO25 OncoAlert

<a href="/YJanjigianMD/">Yelena Y. Janjigian MD</a> plenary session PhIII MATTERHORN periop FLOT +/- durva (up to 1 yr) in stage II-IVa G/GEJ adenoCA (90% PD-L1&gt;1) ➡️ 29% reduction in PD or death, superior EFS (HR 0.71) w/durva arm. pCR 19% vs 7% (52% finished adj durva, 61% finished adj FLOT).

#ASCO25
<a href="/OncoAlert/">OncoAlert</a>
Kamya Sankar MD (@kamyasankar) 's Twitter Profile Photo

Congratulations to our 2nd year Hematology/Oncology fellow Louisa Liu on receiving the ASCO YIA this year for her research on the effects of time restricted eating on the gut microbiome in rectal cancer! Mentored by Dr. Figueiredo and Jun Gong. Cancer at Cedars-Sinai

Congratulations to our 2nd year Hematology/Oncology fellow <a href="/LouisaLiu131/">Louisa Liu</a> on receiving the ASCO YIA this year for her research on the effects of time restricted eating on the gut microbiome in rectal cancer! Mentored by Dr. Figueiredo and <a href="/jgong15/">Jun Gong</a>. <a href="/CSCancerCenter/">Cancer at Cedars-Sinai</a>
Society of Surgical Oncology (@socsurgonc) 's Twitter Profile Photo

Join us for this upcoming webinar! Explore management of sarcomatosis & metastatic GIST, including the role of cytoreduction +/- HIPEC. Learn about patient selection, timing & outcomes. Register now: ow.ly/V5Sy50WbCrW

Join us for this upcoming webinar!

Explore management of sarcomatosis &amp; metastatic GIST, including the role of cytoreduction +/- HIPEC. Learn about patient selection, timing &amp; outcomes.

Register now: ow.ly/V5Sy50WbCrW
Thor Halfdanarson (@oncothor) 's Twitter Profile Photo

Wondering about what to do for NEN patients with peritoneal metastases...? Worry not, check this paper... The Peritoneal Surface Malignancies Consortium Group just dropped a bunch of papers on various cancers Alexandra Gangi, MD Pamela Kunz, MD, FASCO Seth Concors (he/him) acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

Julie Hallet (@halletjulie) 's Twitter Profile Photo

Thanks UofT Surgical Oncology fellows for the honour of 2025 McCready Cup!🙏🏻😀 Always inspired to see you all grow as surgical oncologists. And so special to receive this from the hands of a #surgonc legend I learned so much from, Dr David McCready💛⭐️ (& nice hat trick for the HPB team)

Thanks <a href="/UofTSurgOnc/">UofT Surgical Oncology</a> fellows for the honour of 2025 McCready Cup!🙏🏻😀 
Always inspired to see you all grow as surgical oncologists. And so special to receive this from the hands of a #surgonc legend I learned so much from, Dr David McCready💛⭐️ (&amp; nice hat trick for the HPB team)
Peritoneal Surface Oncology Group International (@psogi_ec) 's Twitter Profile Photo

#PSOGI2025 #PSOGIBarcelona 🏃‍♂️ early bird registrations till 🗓️ 31st July A 🔟 - point guide to the congress ⭐ 1️⃣ 🌟 For beginners in PSM, young surgeons 🧒 , young radiologists 🩻 , young pathologists 🔬 🟡 The congress is preceded by a video 📽️ workshop by Paul H Sugarbaker &

#PSOGI2025  #PSOGIBarcelona 🏃‍♂️ early bird registrations till 🗓️ 31st July
A 🔟 - point guide to the congress 

⭐ 1️⃣ 🌟 For beginners in PSM, young surgeons 🧒 , young radiologists 🩻 , young pathologists 🔬 

🟡 The congress is preceded by a  video 📽️ workshop by <a href="/PSugarbaker/">Paul H Sugarbaker</a> &amp;
Julie Hallet (@halletjulie) 's Twitter Profile Photo

Surveillance over right hemi for appendix #NETs 1-2cm - not only safe but cost-effective💰 Markov analysis from 🇮🇹 ✅Survival is same >98% ✅Surveillance cost-effective - ⬆️with longer FU Varies in 🌎👉🏻less cost-effective South Asia & Africa 📝🔗 link.springer.com/article/10.100…

Surveillance over right hemi for appendix #NETs 1-2cm - not only safe but cost-effective💰

Markov analysis from 🇮🇹
✅Survival is same &gt;98%
✅Surveillance cost-effective - ⬆️with longer FU
Varies in 🌎👉🏻less cost-effective South Asia &amp; Africa

📝🔗 link.springer.com/article/10.100…